Mark Bamforth | General Partner, Kineticos AMR Accelerator Fund I
Kineticos Life Sciences

Mark Bamforth is a General Partner in the Kineticos Anti-Microbial Resistance Accelerator (KAMRA) Fund I. Previously, he founded, grew and sold three PE-backed contract development and manufacturing organizations (CDMO); specifically, Arranta Bio, founded in 2019 to focus on the microbiome, which was sold to Recipharm in 2022, and Brammer Bio which was founded in 2015, supporting cell and gene therapies, which was acquired by Thermo Fisher Scientific in 2019, and Gallus Biopharmaceuticals, which was founded in 2010 to manufacture mAbs, and was sold to Patheon in 2014. Prior to this, Mark was the head of global operations at Genzyme Corporation. Mark serves on the boards of Enterobiotix, Pneumagen, Continuus Pharmaceuticals, Kincell Bio and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.